Contreras ZE, Zuluaga MSX, Cardozo X

Idioma: Español
Referencias bibliográficas: 24
Paginas: 149-159
Archivo PDF: 271.49 Kb.

RESUMEN

La muerte súbita del adulto se presenta de forma inesperada por la evolución, también inesperada, de una enfermedad o por causas desconocidas. Según los expertos, la causa cardiaca está detrás del 85% de los casos de muerte súbita. Cuando el afectado es menor de 30 años, suele asociarse a una cardiopatía congénita o enfermedad de transmisión genética, mientras que si es mayor de 30 años está relacionada con la cardiopatía isquémica, una enfermedad degenerativa de las arterias coronarias. Sin embargo hasta un 15% de las personas que presentan un episodio de muerte súbita tienen un corazón estructuralmente normal, lo que genera un reto en el diagnóstico y tratamiento.

REFERENCIAS (EN ESTE ARTÍCULO)

1. American Heart Association. Heart Disease and Stroke Statistics-2003 update. Dallas (TX)7 American Heart Association; 2002.

2. Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237.

3. Bigger Jr JT et al. for the Coronary Artery Bypass Graft (CABG) Patch trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary artery bypass graft surgery. N Engl J Med 1997; 337: 1569-1575.

4. Bristow MR, Saxon LA, Boehmer J et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-2150.

5. Buxton AE, Lee KL, Fisher JD et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial investigators. N Engl J Med 1999; 341: 1882-1890.

6. Gilman JK, Jalal S, Naccarelli GV. Predicting and preventing sudden death from cardiac causes. Circulation 1994; 90: 1083-1092.

7. Gould PA, Krahn AD. Complications associated with implantable cardioverter-defibrillator replacement in response to device advisories. JAMA 2006; 295: 1907-1911.

8. Harrell Jr FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387.

9. Hohnloser SH, Gersh BJ. Changing late prognosis of acute myocardial infarction: impact on management of ventricular arrhythmias in the era of reperfusion and the implantable cardioverter-defibrillator. Circulation 2003; 107: 941-946.

10. Hohnloser SH, Kuck KH, Dorian P et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004; 351: 2481-2488.

11. Huikuri HV, Makikallio TH, Raatikainen MJ et al. Prediction of sudden cardiac death: appraisal of the studies and methods assessing the risk of sudden arrhythmic death. Circulation 2003; 108: 110-115.

12. Kadish A, Dyer A, Daubert JP et al. for the defibrillators in non-ischemic cardiomyopathy treatment evaluation (DEFINITE) investigators. Prophylactic defibrillator implantation in patients with non-ischemic dilated cardiomyopathy. N Engl J Med 2004; 350: 2151-2158.

13. Lee KL, Pryor DB, Harrell Jr FE et al. Predicting outcome in coronary disease. Statistical models versus expert clinicians. Am J Med 1986; 80: 553-560.

14. Maisel WH, Moynahan M, Zuckerman BD et al. Pacemaker and ICD generator malfunctions: analysis of Food and Drug Administration annual reports. JAMA 2006; 295: 1901-1906.

15. Mark DB, Nelson CL, Anstrom KJ et al. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCDHeFT). Circulation 2006; 114: 135-142.

16. Moss AJ, Hall WJ, Cannom DS et al. for the Multicenter Automatic Defibrillator Implantation Trial Investigators Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmias. N Engl J Med 1996; 335: 1933-1940.

17. Moss AJ, Zareba W, Hall WJ et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883.

18. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: epidemiology, transient risk, and intervention assessment. Ann Intern Med 1993; 119: 1187-1197.

19. Reynolds MR, Cohen DJ, Kugelmass AD et al. The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. J Am Coll Cardiol 2006; 47: 2493-2497.

20. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005; 353: 1471-1480.

21. Singh JP, Hall WJ, McNitt S et al. for the MADIT-II Investigators- Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). J Am Coll Cardiol 2005; 46: 1712-1720.

22. Zheng Z-J, Croft JB, Giles EH et al. Sudden cardiac death in the United States, 1989-1998. Circulation 2001; 104: 2158-2163.

23. Zipes DP, Wellens HJJ. Sudden cardiac death. Circulation 1998; 98: 2334-2351.

24. Zwanziger J, Hall WJ, Dick AW et al. The cost effectiveness of implantable cardioverter-defibrillators: results from the multicenter automatic defibrillator implantation trial (MADIT)-II. J Am Coll Cardiol 2006; 47: 2310-2318.